Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 24:2021:8629039.
doi: 10.1155/2021/8629039. eCollection 2021.

Efficacy and Safety of Paromomycin for Visceral Leishmaniasis: A Systematic Review

Pashupati Pokharel  1 , Rakesh Ghimire  2 , Pratik Lamichhane  1
Affiliations
Review

Efficacy and Safety of Paromomycin for Visceral Leishmaniasis: A Systematic Review

Pashupati Pokharel et al. J Trop Med. .

Abstract

Visceral leishmaniasis, also known as kala-azar is one of the most commonly neglected tropical diseases affecting a large number of rural and resource-limited people in South Asia, Africa, and South America. Paromomycin, an aminoglycoside drug, is frequently used for the treatment of visceral leishmaniasis. Despite limited therapies for visceral leishmaniasis and emerging drug resistance, a proper review on the action of paromomycin for kala-azar is lacking. This systematic review aims to look for the efficacy and safety aspects of paromomycin for the treatment of visceral leishmaniasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Mechanism showing leishmanicidal activity of paromomycin.
Figure 2
Figure 2
PRISMA flow diagram for study selection for the systematic review.
Figure 3
Figure 3
Countries included in the study.
See this image and copyright information in PMC

References

    1. Sundar S., Jha T. K., Thakur C. P., Sinha P. K., Bhattacharya S. K. Injectable paromomycin for Visceral leishmaniasis in India. New England Journal of Medicine. 2007;356(25):2571–2581. doi: 10.1056/nejmoa066536. - DOI - PubMed
    1. Alvar J., Yactayo S., Bern C. Leishmaniasis and poverty. Trends in Parasitology. 2006;22(12):552–557. doi: 10.1016/j.pt.2006.09.004. - DOI - PubMed
    1. Yamey G. The world’s most neglected diseases. British Medical Journal. 2002;325(7357):176–177. doi: 10.1136/bmj.325.7357.176. - DOI - PMC - PubMed
    1. Kassebaum N. J., Arora M. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1859–1922. - PMC - PubMed
    1. Kassebaum N. J., Arora M., Barber R. M., et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the global burden of disease study 2015. The Lancet. 2016;388(10053):1603–1658. - PMC - PubMed

LinkOut - more resources